Impact of Cognitive Behavioral Therapy on PTSD-CVD Link

NCT ID: NCT06429293

Last Updated: 2025-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-01

Study Completion Date

2026-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot randomized controlled trial to assess the impact of a first-line treatment for posttraumatic stress disorder (PTSD) (Cognitive Processing Therapy; CPT) versus waitlist control on mechanisms of cardiovascular disease (CVD) risk. Further, this study will test the hypothesis that CPT reduces CVD risk through its effects on inflammation and autonomic function and that these changes are driven by changes in stress-related neural activity (SNA)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized controlled trial of CPT compared to waitlist control that is testing the effects of CPT on mechanisms of the PTSD-CVD link. Enrollment began in 2023 and is projected to continue through 2026. Participants include individuals with PTSD and CVD risk recruited from the Boston area (N = 30). Treatment assignment is randomized and stratified by sex. Participants are randomized to CPT (n = 15) or waitlist control (n = 15). Potentially eligible participants complete a screening visit to confirm inclusion/exclusion criteria. Upon confirmation of eligibility, participants are scheduled for a baseline session, where they complete surveys, brain and peripheral imaging, and resting measures of autonomic function. Following the baseline visit, participants are randomized into CPT or the waitlist control group. Those randomized to CPT complete sessions via telehealth. Following a 12-week treatment period, participants attend the post-treatment visit, consisting of the same assessments administered at baseline. Participants randomized to waitlist are offered CPT upon completion of the post-treatment visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Posttraumatic Stress Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are randomized to 12 weeks of cognitive processing therapy or waitlist control.
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors
Individuals who interpret images and data will be blinded to assigned intervention

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cognitive processing therapy

12 week treatment period of cognitive processing therapy followed by a post-treatment visit.

Group Type EXPERIMENTAL

Cognitive processing therapy

Intervention Type BEHAVIORAL

The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician

Control waitlist

Participants randomized to waitlist are offered CPT upon completion of the post-treatment visit.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive processing therapy

The active intervention is Cognitive Processing Therapy (CPT) is a gold-standard cognitive behavioral therapy for PTSD. The CPT intervention consists of 12 60-minute sessions teaching skills to challenge trauma-relevant cognitions that are distorted or unhelpful. Trauma-relevant cognitions fall into five themes that are highlighted during treatment: safety, trust, power/control, esteem, and intimacy. The empirical base for CPT is strong with numerous studies demonstrating that it results in significant reduction of PTSD symptoms regardless of trauma type and that it is 89% more effective than control treatment. CPT has been successfully implemented in virtual formats with comparable efficacy levels to that of in-person CPT. CPT sessions for this study will be conducted virtually by a CPT-trained clinician

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age 18-65 years (upper limit chosen to optimize changes in brain activation that diminish with age);
* criterion A trauma exposure and PTSD symptoms (clinically significant symptoms in at least two symptom clusters);
* subclinical atherosclerotic CVD (e.g., coronary, cerebrovascular, or peripheral arterial plaque or calcifications on imaging), clinical atherosclerotic CVD (e.g., myocardial infarction or revascularization), or increased risk for atherosclerotic CVD (i.e., \>2 of hypertension, diabetes mellitus, hyperlipidemia, and active smoking) ability to understand and sign informed consent
* fluent English speaker.

Exclusion Criteria

* history of stroke, brain surgery, seizure
* use of certain CVD medications (e.g., beta-blockers, high-intensity statins \[e.g., rosuvastatin 20/40 mg and atorvastatin 40/80 mg\], PCSK-9 inhibitors);
* psychiatric or cardiovascular medication change within 4 weeks (i.e., stable regimen is allowed);
* currently in PTSD therapy;
* neurological or systemic inflammatory disease/current anti-inflammatory therapy;
* moderate/severe alcohol/substance use disorder;
* current mania/psychosis;
* weight \>300 lbs., claustrophobia, pregnancy, metal implants that are incompatible with magnetic resonance imaging (MRI), or uncontrolled hyperglycemia (for imaging);
* significant radiation exposure (\>2 nuclear tests, computed tomography images, or fluoroscopic procedures) for research purposes during the preceding 12-months.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Heart Association

OTHER

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael T. Osborne

Clinician Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Michael Osborne, MD

Role: CONTACT

6177261843

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michael Osborne, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Edmondson D, Cohen BE. Posttraumatic stress disorder and cardiovascular disease. Prog Cardiovasc Dis. 2013 May-Jun;55(6):548-56. doi: 10.1016/j.pcad.2013.03.004. Epub 2013 Apr 6.

Reference Type BACKGROUND
PMID: 23621964 (View on PubMed)

Edmondson D, von Kanel R. Post-traumatic stress disorder and cardiovascular disease. Lancet Psychiatry. 2017 Apr;4(4):320-329. doi: 10.1016/S2215-0366(16)30377-7. Epub 2017 Jan 19.

Reference Type BACKGROUND
PMID: 28109646 (View on PubMed)

Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995 Dec;52(12):1048-60. doi: 10.1001/archpsyc.1995.03950240066012.

Reference Type BACKGROUND
PMID: 7492257 (View on PubMed)

Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, Pickering RP, Ruan WJ, Huang B, Grant BF. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016 Aug;51(8):1137-48. doi: 10.1007/s00127-016-1208-5. Epub 2016 Apr 22.

Reference Type BACKGROUND
PMID: 27106853 (View on PubMed)

Ehlers A, Suendermann O, Boellinghaus I, Vossbeck-Elsebusch A, Gamer M, Briddon E, Martin MW, Glucksman E. Heart rate responses to standardized trauma-related pictures in acute posttraumatic stress disorder. Int J Psychophysiol. 2010 Oct;78(1):27-34. doi: 10.1016/j.ijpsycho.2010.04.009. Epub 2010 May 5.

Reference Type BACKGROUND
PMID: 20450940 (View on PubMed)

Jovanovic T, Norrholm SD, Sakoman AJ, Esterajher S, Kozaric-Kovacic D. Altered resting psychophysiology and startle response in Croatian combat veterans with PTSD. Int J Psychophysiol. 2009 Mar;71(3):264-8. doi: 10.1016/j.ijpsycho.2008.10.007. Epub 2008 Nov 5.

Reference Type BACKGROUND
PMID: 19013485 (View on PubMed)

Buckley TC, Kaloupek DG. A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med. 2001 Jul-Aug;63(4):585-94. doi: 10.1097/00006842-200107000-00011.

Reference Type BACKGROUND
PMID: 11485112 (View on PubMed)

Pan X, Kaminga AC, Wen SW, Liu A. Catecholamines in Post-traumatic Stress Disorder: A Systematic Review and Meta-Analysis. Front Mol Neurosci. 2018 Dec 4;11:450. doi: 10.3389/fnmol.2018.00450. eCollection 2018.

Reference Type BACKGROUND
PMID: 30564100 (View on PubMed)

Brudey C, Park J, Wiaderkiewicz J, Kobayashi I, Mellman TA, Marvar PJ. Autonomic and inflammatory consequences of posttraumatic stress disorder and the link to cardiovascular disease. Am J Physiol Regul Integr Comp Physiol. 2015 Aug 15;309(4):R315-21. doi: 10.1152/ajpregu.00343.2014. Epub 2015 Jun 10.

Reference Type BACKGROUND
PMID: 26062635 (View on PubMed)

Kim TD, Lee S, Yoon S. Inflammation in Post-Traumatic Stress Disorder (PTSD): A Review of Potential Correlates of PTSD with a Neurological Perspective. Antioxidants (Basel). 2020 Jan 26;9(2):107. doi: 10.3390/antiox9020107.

Reference Type BACKGROUND
PMID: 31991875 (View on PubMed)

Schneider M, Schwerdtfeger A. Autonomic dysfunction in posttraumatic stress disorder indexed by heart rate variability: a meta-analysis. Psychol Med. 2020 Sep;50(12):1937-1948. doi: 10.1017/S003329172000207X. Epub 2020 Aug 28.

Reference Type BACKGROUND
PMID: 32854795 (View on PubMed)

Ge F, Yuan M, Li Y, Zhang W. Posttraumatic Stress Disorder and Alterations in Resting Heart Rate Variability: A Systematic Review and Meta-Analysis. Psychiatry Investig. 2020 Jan;17(1):9-20. doi: 10.30773/pi.2019.0112. Epub 2020 Jan 25.

Reference Type BACKGROUND
PMID: 31995968 (View on PubMed)

Moon E, Lee SH, Kim DH, Hwang B. Comparative Study of Heart Rate Variability in Patients with Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder, or Major Depressive Disorder. Clin Psychopharmacol Neurosci. 2013 Dec;11(3):137-43. doi: 10.9758/cpn.2013.11.3.137. Epub 2013 Dec 24.

Reference Type BACKGROUND
PMID: 24465250 (View on PubMed)

Seligowski AV, Steuber ER, Hinrichs R, Reda MH, Wiltshire CN, Wanna CP, Winters SJ, Phillips KA, House SL, Beaudoin FL, An X, Stevens JS, Zeng D, Neylan TC, Clifford GD, Linnstaedt SD, Germine LT, Bollen KA, Guffanti G, Rauch SL, Haran JP, Storrow AB, Lewandowski C, Musey PI Jr, Hendry PL, Sheikh S, Jones CW, Punches BE, Kurz MC, Murty VP, McGrath ME, Hudak LA, Pascual JL, Seamon MJ, Datner EM, Chang AM, Pearson C, Peak DA, Merchant RC, Domeier RM, Rathlev NK, O'Neil BJ, Sanchez LD, Bruce SE, Miller MW, Pietrzak RH, Joormann J, Barch DM, Pizzagalli DA, Sheridan JF, Luna B, Harte SE, Elliott JM, Koenen KC, Kessler RC, McLean SA, Ressler KJ, Jovanovic T. A prospective examination of sex differences in posttraumatic autonomic functioning. Neurobiol Stress. 2021 Aug 21;15:100384. doi: 10.1016/j.ynstr.2021.100384. eCollection 2021 Nov.

Reference Type BACKGROUND
PMID: 34485632 (View on PubMed)

Seligowski AV, Grewal SS, Abohashem S, Zureigat H, Qamar I, Aldosoky W, Gharios C, Hanlon E, Alani O, Bollepalli SC, Armoundas A, Fayad ZA, Shin LM, Osborne MT, Tawakol A. PTSD increases risk for major adverse cardiovascular events through neural and cardio-inflammatory pathways. Brain Behav Immun. 2024 Mar;117:149-154. doi: 10.1016/j.bbi.2024.01.006. Epub 2024 Jan 11.

Reference Type BACKGROUND
PMID: 38218349 (View on PubMed)

O'Donovan A, Neylan TC, Metzler T, Cohen BE. Lifetime exposure to traumatic psychological stress is associated with elevated inflammation in the Heart and Soul Study. Brain Behav Immun. 2012 May;26(4):642-9. doi: 10.1016/j.bbi.2012.02.003. Epub 2012 Feb 15.

Reference Type BACKGROUND
PMID: 22366689 (View on PubMed)

Tawakol A, Ishai A, Takx RA, Figueroa AL, Ali A, Kaiser Y, Truong QA, Solomon CJ, Calcagno C, Mani V, Tang CY, Mulder WJ, Murrough JW, Hoffmann U, Nahrendorf M, Shin LM, Fayad ZA, Pitman RK. Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. Lancet. 2017 Feb 25;389(10071):834-845. doi: 10.1016/S0140-6736(16)31714-7. Epub 2017 Jan 12.

Reference Type BACKGROUND
PMID: 28088338 (View on PubMed)

Lima BB, Hammadah M, Wilmot K, Pearce BD, Shah A, Levantsevych O, Kaseer B, Obideen M, Gafeer MM, Kim JH, Sullivan S, Lewis TT, Weng L, Elon L, Li L, Bremner JD, Raggi P, Quyyumi A, Vaccarino V. Posttraumatic stress disorder is associated with enhanced interleukin-6 response to mental stress in subjects with a recent myocardial infarction. Brain Behav Immun. 2019 Jan;75:26-33. doi: 10.1016/j.bbi.2018.08.015. Epub 2018 Aug 30.

Reference Type BACKGROUND
PMID: 30172946 (View on PubMed)

Myers B. Corticolimbic regulation of cardiovascular responses to stress. Physiol Behav. 2017 Apr 1;172:49-59. doi: 10.1016/j.physbeh.2016.10.015. Epub 2016 Oct 25.

Reference Type BACKGROUND
PMID: 27793557 (View on PubMed)

Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB, Peters PM, Metzger LJ, Dougherty DD, Cannistraro PA, Alpert NM, Fischman AJ, Pitman RK. Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry. 2004 Feb;61(2):168-76. doi: 10.1001/archpsyc.61.2.168.

Reference Type BACKGROUND
PMID: 14757593 (View on PubMed)

Shin LM, Wright CI, Cannistraro PA, Wedig MM, McMullin K, Martis B, Macklin ML, Lasko NB, Cavanagh SR, Krangel TS, Orr SP, Pitman RK, Whalen PJ, Rauch SL. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry. 2005 Mar;62(3):273-81. doi: 10.1001/archpsyc.62.3.273.

Reference Type BACKGROUND
PMID: 15753240 (View on PubMed)

Williams LM, Kemp AH, Felmingham K, Barton M, Olivieri G, Peduto A, Gordon E, Bryant RA. Trauma modulates amygdala and medial prefrontal responses to consciously attended fear. Neuroimage. 2006 Jan 15;29(2):347-57. doi: 10.1016/j.neuroimage.2005.03.047. Epub 2005 Oct 10.

Reference Type BACKGROUND
PMID: 16216534 (View on PubMed)

Stevens JS, Jovanovic T, Fani N, Ely TD, Glover EM, Bradley B, Ressler KJ. Disrupted amygdala-prefrontal functional connectivity in civilian women with posttraumatic stress disorder. J Psychiatr Res. 2013 Oct;47(10):1469-78. doi: 10.1016/j.jpsychires.2013.05.031. Epub 2013 Jul 1.

Reference Type BACKGROUND
PMID: 23827769 (View on PubMed)

Osborne MT, Abohashem S, Zureigat H, Abbasi TA, Tawakol A. Multimodality molecular imaging: Gaining insights into the mechanisms linking chronic stress to cardiovascular disease. J Nucl Cardiol. 2021 Jun;28(3):955-966. doi: 10.1007/s12350-020-02424-6. Epub 2020 Nov 17.

Reference Type BACKGROUND
PMID: 33205328 (View on PubMed)

Manthey A, Sierk A, Brakemeier EL, Walter H, Daniels JK. Does trauma-focused psychotherapy change the brain? A systematic review of neural correlates of therapeutic gains in PTSD. Eur J Psychotraumatol. 2021 Aug 6;12(1):1929025. doi: 10.1080/20008198.2021.1929025. eCollection 2021.

Reference Type BACKGROUND
PMID: 34394855 (View on PubMed)

Aupperle RL, Allard CB, Simmons AN, Flagan T, Thorp SR, Norman SB, Paulus MP, Stein MB. Neural responses during emotional processing before and after cognitive trauma therapy for battered women. Psychiatry Res. 2013 Oct 30;214(1):48-55. doi: 10.1016/j.pscychresns.2013.05.001. Epub 2013 Aug 2.

Reference Type BACKGROUND
PMID: 23916537 (View on PubMed)

Santarnecchi E, Bossini L, Vatti G, Fagiolini A, La Porta P, Di Lorenzo G, Siracusano A, Rossi S, Rossi A. Psychological and Brain Connectivity Changes Following Trauma-Focused CBT and EMDR Treatment in Single-Episode PTSD Patients. Front Psychol. 2019 Feb 25;10:129. doi: 10.3389/fpsyg.2019.00129. eCollection 2019.

Reference Type BACKGROUND
PMID: 30858808 (View on PubMed)

Helpman L, Marin MF, Papini S, Zhu X, Sullivan GM, Schneier F, Neria M, Shvil E, Malaga Aragon MJ, Markowitz JC, Lindquist MA, Wager T, Milad M, Neria Y. Neural changes in extinction recall following prolonged exposure treatment for PTSD: A longitudinal fMRI study. Neuroimage Clin. 2016 Oct 10;12:715-723. doi: 10.1016/j.nicl.2016.10.007. eCollection 2016.

Reference Type BACKGROUND
PMID: 27761402 (View on PubMed)

Zhu X, Suarez-Jimenez B, Lazarov A, Helpman L, Papini S, Lowell A, Durosky A, Lindquist MA, Markowitz JC, Schneier F, Wager TD, Neria Y. Exposure-based therapy changes amygdala and hippocampus resting-state functional connectivity in patients with posttraumatic stress disorder. Depress Anxiety. 2018 Oct;35(10):974-984. doi: 10.1002/da.22816. Epub 2018 Sep 10.

Reference Type BACKGROUND
PMID: 30260530 (View on PubMed)

Abdallah CG, Averill CL, Ramage AE, Averill LA, Alkin E, Nemati S, Krystal JH, Roache JD, Resick P, Young-McCaughan S, Peterson AL, Fox P; STRONG STAR Consortium. Reduced Salience and Enhanced Central Executive Connectivity Following PTSD Treatment. Chronic Stress (Thousand Oaks). 2019 Jan-Feb;3:2470547019838971. doi: 10.1177/2470547019838971. Epub 2019 Apr 15.

Reference Type BACKGROUND
PMID: 31008419 (View on PubMed)

Watkins LL, LoSavio ST, Calhoun P, Resick PA, Sherwood A, Coffman CJ, Kirby AC, Beaver TA, Dennis MF, Beckham JC. Effect of cognitive processing therapy on markers of cardiovascular risk in posttraumatic stress disorder patients: A randomized clinical trial. J Psychosom Res. 2023 Jul;170:111351. doi: 10.1016/j.jpsychores.2023.111351. Epub 2023 May 2.

Reference Type BACKGROUND
PMID: 37178469 (View on PubMed)

Weathers FW, Bovin MJ, Lee DJ, Sloan DM, Schnurr PP, Kaloupek DG, Keane TM, Marx BP. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol Assess. 2018 Mar;30(3):383-395. doi: 10.1037/pas0000486. Epub 2017 May 11.

Reference Type BACKGROUND
PMID: 28493729 (View on PubMed)

Radfar A, Abohashem S, Osborne MT, Wang Y, Dar T, Hassan MZO, Ghoneem A, Naddaf N, Patrich T, Abbasi T, Zureigat H, Jaffer J, Ghazi P, Scott JA, Shin LM, Pitman RK, Neilan TG, Wood MJ, Tawakol A. Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome. Eur Heart J. 2021 May 14;42(19):1898-1908. doi: 10.1093/eurheartj/ehab029.

Reference Type BACKGROUND
PMID: 33768230 (View on PubMed)

Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, Fayad ZA, Lehrer-Graiwer J, Korsgren M, Figueroa AL, Fredrickson J, Rubin B, Hoffmann U, Truong QA, Min JK, Baruch A, Nasir K, Nahrendorf M, Tawakol A. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging. 2015 Feb;8(2):121-30. doi: 10.1016/j.jcmg.2014.10.009. Epub 2015 Jan 7.

Reference Type BACKGROUND
PMID: 25577441 (View on PubMed)

Hariri AR, Bookheimer SY, Mazziotta JC. Modulating emotional responses: effects of a neocortical network on the limbic system. Neuroreport. 2000 Jan 17;11(1):43-8. doi: 10.1097/00001756-200001170-00009.

Reference Type BACKGROUND
PMID: 10683827 (View on PubMed)

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.

Reference Type BACKGROUND
PMID: 8598068 (View on PubMed)

Asmundson GJG, Thorisdottir AS, Roden-Foreman JW, Baird SO, Witcraft SM, Stein AT, Smits JAJ, Powers MB. A meta-analytic review of cognitive processing therapy for adults with posttraumatic stress disorder. Cogn Behav Ther. 2019 Jan;48(1):1-14. doi: 10.1080/16506073.2018.1522371. Epub 2018 Oct 18.

Reference Type BACKGROUND
PMID: 30332919 (View on PubMed)

Kline AC, Cooper AA, Rytwinksi NK, Feeny NC. Long-term efficacy of psychotherapy for posttraumatic stress disorder: A meta-analysis of randomized controlled trials. Clin Psychol Rev. 2018 Feb;59:30-40. doi: 10.1016/j.cpr.2017.10.009. Epub 2017 Nov 21.

Reference Type BACKGROUND
PMID: 29169664 (View on PubMed)

Watts BV, Schnurr PP, Mayo L, Young-Xu Y, Weeks WB, Friedman MJ. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry. 2013 Jun;74(6):e541-50. doi: 10.4088/JCP.12r08225.

Reference Type BACKGROUND
PMID: 23842024 (View on PubMed)

Held P, Kovacevic M, Petrey K, Meade EA, Pridgen S, Montes M, Werner B, Miller ML, Smith DL, Kaysen D, Karnik NS. Treating posttraumatic stress disorder at home in a single week using 1-week virtual massed cognitive processing therapy. J Trauma Stress. 2022 Aug;35(4):1215-1225. doi: 10.1002/jts.22831. Epub 2022 Mar 25.

Reference Type BACKGROUND
PMID: 35338534 (View on PubMed)

Held P, Coleman JA, Petrey K, Klassen BJ, Pridgen S, Bravo K, Smith DL, Van Horn R. A case series examining PTSD and depression symptom reductions over the course of a 2-week virtual intensive PTSD treatment program for veterans. Psychol Trauma. 2022 May;14(4):615-623. doi: 10.1037/tra0001106. Epub 2021 Aug 26.

Reference Type BACKGROUND
PMID: 34435816 (View on PubMed)

Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, Subramanian SS, Abdelbaky A, Rudd JH, Farkouh ME, Nunes IO, Beals CR, Shankar SS. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013 Sep 3;62(10):909-17. doi: 10.1016/j.jacc.2013.04.066. Epub 2013 May 30.

Reference Type BACKGROUND
PMID: 23727083 (View on PubMed)

Bourassa KJ, Hendrickson RC, Reger GM, Norr AM. Posttraumatic Stress Disorder Treatment Effects on Cardiovascular Physiology: A Systematic Review and Agenda for Future Research. J Trauma Stress. 2021 Apr;34(2):384-393. doi: 10.1002/jts.22637. Epub 2020 Dec 5.

Reference Type BACKGROUND
PMID: 33277952 (View on PubMed)

Gan WQ, Buxton JA, Scheuermeyer FX, Palis H, Zhao B, Desai R, Janjua NZ, Slaunwhite AK. Risk of cardiovascular diseases in relation to substance use disorders. Drug Alcohol Depend. 2021 Dec 1;229(Pt A):109132. doi: 10.1016/j.drugalcdep.2021.109132. Epub 2021 Oct 27.

Reference Type BACKGROUND
PMID: 34768052 (View on PubMed)

Byers AL, Covinsky KE, Neylan TC, Yaffe K. Chronicity of posttraumatic stress disorder and risk of disability in older persons. JAMA Psychiatry. 2014 May;71(5):540-6. doi: 10.1001/jamapsychiatry.2014.5.

Reference Type BACKGROUND
PMID: 24647756 (View on PubMed)

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659. No abstract available.

Reference Type BACKGROUND
PMID: 30700139 (View on PubMed)

Ellis R, Sinnott S, Karam K, Assefa A, Osborne M, Seligowski A. Impact of cognitive behavioural therapy on neural, inflammatory, & autonomic markers in a sample with PTSD and cardiovascular risk: protocol for a pilot randomised controlled trial. Eur J Psychotraumatol. 2024;15(1):2378618. doi: 10.1080/20008066.2024.2378618. Epub 2024 Jul 24.

Reference Type DERIVED
PMID: 39045795 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023P001621

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment for PTSD and Tinnitus
NCT07106593 RECRUITING NA
Cognitive Therapy for PTSD in Addiction Treatment
NCT00685451 COMPLETED PHASE1/PHASE2